At the core of Beam Therapeutics’ innovation is its proprietary base editing technology

At the core of Beam Therapeutics’ innovation is its proprietary base editing technology. Unlike traditional gene editing methods, base editing allows for precise and irreversible conversion of one DNA base into another, without creating double strand breaks in the DNA. This precision reduces the risk of unintended genetic changes and enhances the safety and efficacy of the therapy. Adenine Base Editors (ABEs): ABEs convert adenine (A) to guanine (G), enabling the correction of G>A point mutations, which are responsible for numerous genetic disorders.Cytosine Base Editors (CBEs): CBEs convert cytosine (C) to thymine (T), addressing C>T point mutations found in many genetic diseases. Beam Therapeutics is developing base editing therapies to correct mutations in the beta globin gene, offering potential curative treatments for these debilitating blood disorders. Cancer Immunotherapy: The company is exploring the use of base editing to engineer immune cells for enhanced an− ti−tumor activity, aiming to develop next−generation cancer immunotherapies.